{"id":"W4410804826","doi":"10.1200/jco.2025.43.16_suppl.1003","title":"INAVO120: Phase III trial final overall survival (OS) analysis of first-line inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC).","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Palbociclib; Medicine; Placebo; Oncology; Internal medicine; Pharmacology; Gynecology; Cancer; Estrogen receptor; Metastatic breast cancer; Breast cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.00224687,0.0007791008,0.005935885,0.00108343,0.0001460086,0.00002733929,0.0005723579,0.0005816914,0.0004034762],"category_scores_gemma":[0.001701434,0.0005929723,0.001253456,0.002414412,0.001047031,0.0005557023,0.0001629992,0.002387712,0.000003336439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001572067,"about_ca_system_score_gemma":0.00301833,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001422275,"about_ca_topic_score_gemma":0.004208294,"domain_scores_codex":[0.9896681,0.001306245,0.005856301,0.0009216512,0.001313393,0.0009342855],"domain_scores_gemma":[0.9868767,0.004277435,0.005140035,0.0006139542,0.002467004,0.0006248392],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8505651,0.01350316,0.04505583,0.000105463,0.008109291,0.0007051943,0.0006033184,0.003205314,0.00044731,0.00009518014,0.0003140072,0.07729088],"study_design_scores_gemma":[0.6486465,0.04814304,0.2878221,0.001453156,0.006207226,0.00007549316,0.0007583991,0.0005582498,0.0005803677,0.0002650635,0.004835531,0.0006549372],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9882278,0.0008385174,0.0008806533,0.005634335,0.001359578,0.001778515,0.0005905132,0.00003275739,0.0006573532],"genre_scores_gemma":[0.9933153,0.002144713,0.002374522,0.0008843008,0.0006888295,0.0001087782,0.0001023821,0.00007257259,0.0003086127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2427663,"threshold_uncertainty_score":0.9999138,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03850210338684483,"score_gpt":0.4100375686141059,"score_spread":0.3715354652272611,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}